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Chapter 4
Pharmacokinetics of Anticoagulant 
Rodenticides in Target and Non-target 
Organisms
Katherine E. Horak, Penny M. Fisher, and Brian Hopkins
1  Introduction
The concentration of a compound at the site of action is a determinant of its toxicity. 
This principle is affected by a variety of factors including the chemical properties of 
the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route 
of exposure, and physiological properties of the organism. Many compounds have 
to undergo chemical changes, biotransformation, into more toxic or less toxic forms. 
Because of all of these variables, predicting toxic effects and performing risk assess-
ments of compounds based solely on dose are less accurate than those that include 
data on absorption, distribution, metabolism (biotransformation), and excretion of 
the compound. These factors are commonly referred to as ADME. The quantitative 
study of these properties is called pharmacokinetics and often encompasses the 
determination of compound concentrations in tissues of interest including blood and 
the time course of absorption, metabolism, and excretion. A goal of pharmacokinet-
ics is an understanding of the relationship between dose and the concentration of the 
active compound at the target site. Toxicokinetics is a “unique expansion of phar-
macokinetics”, with doses being much greater than those in pharmacokinetic stud-
ies (Welling 1995). This is a complicated task, especially for anticoagulant 
rodenticides (ARs), as exposure (dose) frequently occurs over multiple days and 
can result from consumption of poisoned animals containing varying concentration 
of ARs and their metabolites, not simply a toxic bait.
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Although ARs have been in use for decades, there are limited data on the ADME 
of these compounds for non-target animals. Most of the data have been derived from 
laboratory strains of rodents as a traditional model system. Current understanding 
of the pharmacokinetics (how the exposed animal affects the compound?) and phar-
macodynamics (how the compound affects the exposed animal?) of ARs tend to 
focus on how their toxic effects are mediated in a particular species (e.g., Littin et al. 
2002). Such information is essential to predicting the efficacy of ARs in rodent 
management and adverse effects of their use on non-target species, and allows for a 
more accurate comparison of various classes of ARs (first-, intermediate- and 
second- generation). When information about the ADME properties of an AR are 
combined with data such as binding affinities and physiological/ecological charac-
teristics of an organism, more accurate risk assessments can be made. These hazard 
and risk assessments are important as the US EPA and other regulatory agencies 
include pharmacokinetic data and models in their work plans and formal ecological 
risk assessments.
2  Formulations
All ARs currently on the market are formulated into palatable baits for oral delivery 
to targeted rodent pests. Typically, bait formulations are based on cereal grain made 
into compressed blocks or pellets along with smaller portions of binding, flavoring, 
non-target deterrents and coloring (blue or green) agents. A wax or water proofing 
ingredient is included in some formulations. Such bait formulations impart low 
production costs plus relative safety and ease of application, usually in a bait station. 
Other types of specialized formulations do exist but have more limited applications 
in particular environmental conditions, for example liquid concentrates that can be 
diluted for use in areas where an abundant food source is present, or in areas where 
there is little or no water supply. Similarly, concentrated anticoagulant tracking 
powders are available for use when conventional baits may not be appropriate or 
accepted (e.g., dusting into rat burrows that are likely to lead into buildings and into 
wall voids which are not accessible for normal bait placement).
3  Routes of Exposure
While current bait formulations rely on voluntary ingestion of sufficient quantities 
for efficacy against target animals, they also present the potential for unwanted 
primary exposure of other animals that access and eat bait. Secondary oral exposure 
to ARs can also occur via ingestion of animal tissues that contain AR residues; this 
exposure pathway has emerged as a particular concern for wildlife species that prey 
on rodents or scavenge the carcasses of poisoned animals.
K.E. Horak et al.
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Besides their use as rodenticides some anticoagulant compounds, particularly 
warfarin (2001) and historically diphacinone (e.g. Field et al. (1952)), have wide 
application in human anticoagulation therapy. Human exposure to anticoagulants 
through rodenticide bait can occur (Tran and King 2015; Watt et al. 2005) and is 
most typically oral, whether accidental (e.g., exploratory ingestion by very young 
children) or deliberate (e.g., attempts at self-harm) (e.g. Bruno et al. 2000). Less 
commonly dermal (Spiller et al. 2003) or inhalation (Lee et al. 2014) exposure of 
humans has been documented in the context of occupational exposure during manu-
facture or inappropriate application of bait for rodent control. Development and 
refinement of human therapies and treatments for anticoagulant poisoning have sub-
stantially driven research and clinical evaluations of pharmacokinetics and responses 
of blood coagulation indices (e.g., prothrombin time following treatment regimens 
with Vitamin K1) (Hanslik and Prinseau 2004).
4  Absorption, Distribution, Metabolism and Excretion
A study by Subota et al. (2016) examined the absorption and physiological effects 
of a dermally applied solution of sodium warfarin in laboratory rats (Rattus norvegi-
cus). They found that dermal applications of 10 μg and 100 μg of warfarin signifi-
cantly increased prothrombin time (PT) when compared to controls indicating that 
the compound is absorbed through the skin in quantities sufficient to exert its phar-
macological effect. The dermal absorption of the coumarin backbone of the class of 
anticoagulants has also been studied. The absorption of coumarin in both ethanol 
and oil:water emulsion was tested using both human and rat skin (Yourick and 
Bronaugh 1997). In both human abdominal and rat dorsal skin, absorption was 
greater in the emulsion vehicle and the majority of the absorption occurred within 
six hours of application. No coumarin metabolism was found in these experiments, 
suggesting that transdermal exposure to coumarins will result in a higher systemic 
exposure to the active parent compound than oral exposure prior to first pass metab-
olism. Additional studies of skin absorption of coumarin also found that it was 
extensively absorbed through human, rat, and mouse skin which was attributed to 
the compound’s lipophilicity (Beckley-Kartey et al. 1997).
Active concentrations in bait are typically 0.02–0.05 g/kg for second-generation 
ARs (SGARs) and 0.25–0.5 for the less potent first-generation ARs (FGARs). Here 
we focus on oral exposure resulting from ingestion of bait containing an AR and 
also ingestion of animal tissue that contains residual anticoagulant concentrations. 
Anticoagulants are generally considered to be well-absorbed through the gastroin-
testinal tract (Watt et al. 2005), presumably within a few hours. Wright and Hayden 
(1955) suggested that the efficacy of absorption of a coumarin derivative in rats 
could be reduced by the presence of high fat levels in gut contents. Berny et al. 
(2006) indicated that anticoagulants (warfarin, chlorophacinone and bromadiolone) 
underwent very little, if any, degradation by microflora in sheep rumen.
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After absorption across the intestinal epithelium, anticoagulant compounds enter 
the hepatic circulation prior to being distributed throughout the whole body of 
mammals. In birds, a fraction of the blood from the gastrointestinal tract is directed 
to the kidneys through the coccygeomesenteric vein. This can dramatically decrease 
the anticoagulant concentration in the systemic circulation as the compounds are 
metabolized by the liver largely through the action of cytochrome P450 isozymes 
(CYPs). Ring hydroxylation is thought to be an important biotransformation step 
for the coumarin-based anticoagulant compounds, although this is less well 
described for the indandione compounds. Hydroxylated metabolites can further 
undergo conjugation with glucuronic acid prior to entering the systemic circulation, 
and potentially undergoing enterohepatic recirculation. This can affect the amount 
of compound that reaches target locations. Enterohepatic recirculation of unmetab-
olized parent compound, may partly explain the higher toxicity of some of the 
second- generation anticoagulants (Bachmann and Sullivan 1983).
Metabolism, distribution, and excretion of ARs are affected by numerous factors. 
Hepatic metabolism of ARs exhibits a biphasic profile. Initial metabolism is rapid, 
often clearing a large percentage of the compound within the first days following 
exposure. In the terminal phase of hepatic metabolism, clearance of anticoagulant 
compound occurs more slowly leading to the low residual levels of SGARs often 
found for long periods of time post-exposure. Anticoagulant rodenticides, particu-
larly warfarin, are highly protein-bound to serum albumin (Watt et al. 2005). This 
affects their distribution to active sites and therefore necessitates higher bait concen-
trations to ensure adequate unbound compound is available to interact with target 
proteins. Some second-generation ARs, such as brodifacoum and flocoumafen, 
appear to undergo relatively little biotransformation being excreted largely as 
unchanged parent compound in feces. This is in contrast to first-generation com-
pounds that appear to undergo more extensive metabolism, with a range of metabo-
lite compounds excreted in urine.
In addition to providing information about effects to the primary target animal, a 
firm understanding of the ADME characteristics of ARs will help in assessing the 
potential risks they pose to non-target species. The information provided below 
serves as a summary of studies of the pharmacokinetics of AR in non-target species. 
When examined together, these studies give a general understand of the ADME 
characteristics of ARs in non-target species. However, the paucity of data on some 
compounds and species indicate that additional studies should be undertaken to 
improve our understanding of the potential effects across species.
4.1  Warfarin
Warfarin is a racemic mixture of the R and S stereoisomers with the (S)-isomer 
having approximately seven-fold greater activity than the (R)-isomer (Breckenridge 
and L’E Orme 1972). Cytochrome P450 mediated warfarin metabolism is well 
established in mammalian species and has been employed as a determinant of 
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warfarin sensitivity. The stereoisomers are metabolized by different phase 1 
enzymes; the predominant metabolism of the S isomer in humans is via CYP2C9 
whereas metabolism of R-warfarin is mainly via CYP3A4 with involvement of 
CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18 and CYP2C19 (Rettie et  al. 
1992; Ngui et al. 2001; Zhang et al. 1995; Wienkers et al. 1996). In rats, CYP1A, 
CYP2B, CYP2C, and CYP3A isoforms are known to metabolize warfarin 
(Guengerich et al. 1982). This phase 1 metabolism is achieved through the produc-
tion of relatively inactive hydroxywarfarins – 6-, 7-, 8-, 10-, and 4′-hydroxywarfarin 
(Kaminsky and Zhang 1997; Jones and Miller 2011). It has been reported that one 
of the mechanisms that induces warfarin-resistance in rats (Rattus rattus) is elevated 
CYP-mediated warfarin metabolism (Ishizuka et al. 2007). Phase II metabolism of 
warfarin has not been well studied, although it is known that sulfated and glucuronyl 
conjugates (Sutcliffe et al. 1987) can be formed and that the primary metabolites are 
made more water-soluble by phase II enzymes (Jansing et al. 1992). It has been sug-
gested that the glucuronide metabolites are principally formed in the kidney in man 
(Kaminsky and Zhang 1997). Elimination of warfarin is predominantly renal; how-
ever, salivary excretion has also been described in rabbits (Sakai et al. 1983).
In contrast to rats, it appears that the major CYP isoforms of bird species are dif-
ferent to the predominant isoforms in mammals. The dominant CYP isoforms of 
bird species are thought to be CYP2H1/2 (resembles rat CYP2B1/2), CYP1A4/5 
(resembles rat CYP1A1/2) or an inducible form that resembles rat CYP2E (Louis 
et  al. 1993). Some bird species demonstrate a warfarin metabolic activity that is 
significantly greater than in rats (e.g., in chickens, Gallus domesticus, warfarin met-
abolic activity to hydroxylated forms of warfarin was observed to be >5-fold greater 
than rats). However, such activity is quite variable among avian species (Table 4.1). 
This difference in activity between mammals and birds and among avian species 
corresponds directly to the rank order of warfarin susceptibility, as demonstrated in 
owls (snowy owl, Bubo scandiacus and great horned owl, Bubo virginianus) which 
show very little warfarin metabolism compared with rodents and other bird species. 
This low metabolism may also slow the elimination rate of warfarin which sug-
gests that owls possess a low ability to detoxify anticoagulant rodenticides in gen-
eral, a contributing factor perhaps to the high frequency of reported poisoning 
accidents in these species. In addition to the usual five major hydroxylated metabo-
lites identified in mammals, birds also appear to produce a unique  warfarin alcohol 
Table 4.1 Mean metabolic activities (pmol/min/nmol P450) of each of the hydroxylated forms of 
warfarin in rat, chicken, ostrich and mallard (Anas platyrhynchos) owl includes snowy owl and 
great horned owl
Species 4′-OH 6′-OH 7′-OH 8′-OH 10′-OH Total
Rat 92.8 48.5 14.9 2.3 37.4 196.0
Chicken 1204.0 294.5 113.7 43.4 4.5 1660.2
Ostrich 523.4 68.0 17.2 30.4 ND 638.0
Mallard 96.8 18.2 10.5 ND 9.1 134.6
Owl 25.9 2.6 ND 1.5 ND 32.0
Adapted from Watanabe et al. (2010)
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metabolite (Table 4.1) (Watanabe et al. 2010). This suggests that birds have an abil-
ity to uniquely metabolize warfarin, which differs from that of rats and human 
(Rettie et al. 1992; Ngui et al. 2001). Saengtienchai et al. (2011) propose that in 
chickens, this is through activity of aldehyde oxidase in cytosol rather than being a 
CYP-mediated pathway.
Interestingly, another study by the same group (Watanabe et al. 2015) found that 
the half-life of warfarin in chicken was longer than in most mammalian species that 
possess greater warfarin metabolic ability. This suggests that protein binding of 
warfarin in the chicken (primarily to albumin in the plasma) may be greater in birds 
which results in the longer half-life and less toxicity despite the high metabolic abil-
ity. Watanabe and coworkers postulated that since the albumin content in birds is 
less than in mammals, it might have greater warfarin-binding capacity. In regards to 
other bird species, Watanabe et al. (2015) also characterized warfarin metabolism in 
liver microsomes of the crow (Corvus macrorhynchos), mallard and ostrich (Struthio 
camelus). Microsomes from chickens and crows had higher activity than those from 
mallard or ostrich, further suggesting that the half-life of warfarin may be variable 
among avian species.
Warfarin has been shown to interact with the ABCB1 transporter in human liver 
(Wadelius et  al. 2004). In modelling human pharmacodynamics, Holford (1986) 
determined that warfarin is essentially completely absorbed, reaching a maximum 
plasma concentration between 2 and 6 h. It distributes into a small volume of distri-
bution (10 L/70 kg) and is eliminated with a very low clearance (0.2 L/h/70 kg) and 
elimination half-life is about 35 h (Holford 1986). Warfarin also undergoes exten-
sive biliary (enterohepatic) recycling with approximately 10% of administered dose 
of 14C–warfarin excreted by rats within 5 h after intraperitoneal injection (Powell 
et al. 1977). This latter study found relatively little radioactivity in the feces, indicat-
ing that considerable enterohepatic recycling takes place with extensive gut flora-
mediated hydrolysis of warfarin conjugates occurring. This was confirmed by 
Remmel and coworkers (1981) who identified that there was a significant decrease 
in the volume of distribution of warfarin in antibiotic-treated rats.
The time course of warfarin concentrations in the serum, liver, kidneys, muscle, 
and abdominal fat of male Sprague-Dawley rats after intravenous injection of a 
0.25  mg/kg or 1.0  mg/kg body weight has been determined (Levy et  al. 2003). 
Warfarin concentrations in serum declined exponentially by over one order of mag-
nitude between 80 and 240 h after intravenous injection of a 0.25 mg/kg or 1.0 mg/
kg dose. During this time, concentrations in other tissues declined more slowly. In 
another study, S-warfarin concentrations in serum and liver were followed for 
approximately 50 days after intravenous injection of 1 mg/kg dose. This revealed a 
very slow terminal elimination phase in serum nearly parallel to the decline in liver 
warfarin concentrations. The residues of warfarin in liver of rats over time after a 
single sublethal dose declined from 1.26 μg/g at 1 week, to below the limit of detec-
tion (<0.1 mg/g) at 24 weeks after dosing (combined results of 2 trials), with an 
estimated liver-elimination half-life of 26.2 days (Fisher et al. 2003) (Table 4.2).
Although an effective anticoagulant, because of its low molecular weight, warfa-
rin can readily cross the placenta; therefore, administration during pregnancy has 
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consequences in regards to reduced mean birth weight (Sareli et  al. 1989) and 
increased percentage of abortion, stillbirth, and neonatal death incidences (Sareli 
et al. 1989; Ginsberg and Hirsh 1989). The majority of the information regarding 
coumarin anticoagulants in pregnancy has been derived from the use of warfarin to 
prevent pulmonary embolism in pregnant women (Ginsberg and Hirsh 1989; 
Greaves 1993). Howe and Webster (1992) showed that neonatal rats administered 
subcutaneous warfarin and Vitamin K1 for up to 12 weeks developed marked maxil-
lonasal hypoplasia. In humans, warfarin is a known teratogen that induces nasal 
hypoplasia that can lead to neonatal respiratory distress and upper airway obstruc-
tion; stippled epiphyses marked by multiple ossification centers that severely deform 
the long bone that could lead to dwarfism, and central nervous system defects such 
as microcephaly, hydrocephalus, agenesis of corpus callosum, and Dandy-Walker 
malformation have also been associated with warfarin exposure (Ginsberg and 
Hirsh 1989). In addition, eye anomalies are also evidenced (optic atrophy, microph-
thalmia, and Peter anomaly of eye) (Hall 1990).
Pharmacokinetic studies of warfarin enantiomers indicate that significant differ-
ences exist in clearance of S- and R-warfarin in humans, rats and rabbits (Hignite 
et al. 1980). These findings have also been confirmed in cats (Smith et al. 2000a), 
with the enantiomers being highly protein-bound (>99%) at all concentrations eval-
uated, as described in other species (Brown et al. 1979). However, the binding affin-
ity for both enantiomers to human and rat albumin appears to be significantly greater 
than other species evaluated (Panjehshahin et  al. 1992), and is enantioselective 
appearing to have higher binding affinity for S-warfarin (Park 1988; Brown et al. 
1979). Warfarin has also been detected in the albumen and yolk of hens eggs after 
warfarin ingestion (Kammerer et  al. 1998). The study suggests that the kinetics 
involved are two fold – the first a direct diffusion of warfarin across the magnum 
Table 4.2 Half-life values reported for warfarin in blood and liver
Species Plasma t ½
Liver t ½ 
(days) Reference
Norway rat 26.2 Fisher et al. (2003)
House mouse
Cat
Human
Human
Human (R isomer)
Human (S isomer)
Rats
Rats (ex-germ free)
14.9 days*
26.2 h
42 h
35 h
20–60 h
18–35 h
6–41 h
18.2 h
66.8 Vandenbroucke et al. (2008)
Smith et al. (2000b)
O’Reilly et al. (1963 )
Holford (1986)
Breckenridge et al. (1974); Hewick and 
McEwen (1973); O’Reilly (1973, 1976; 
O’Reilly et al. (1971); Orme and 
Breckenridge (1976)
Yacobi et al. (1975) 
Remmel et al. (1981)
Chicken 27.4 h (male)
34.0 h (female)
Watanabe et al. (2015)
Plasma half-life significantly longer than that reported in other species (perhaps an artifact of high 
dose levels).
4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms
94
wall of the chicken into the egg’s albumen one day after ingestion, and the second a 
later accumulation at 3–4 days which appears to arise from liver depots. Although 
appearing to be an effective elimination route, the amount of excretion into the egg 
was minor compared to that excreted in urine and feces. However, as only the levels 
of the parent warfarin were measured, the elimination efficiency and accumulated 
levels of any metabolites remains unknown.
4.2  Coumatetralyl
The Danish Environmental Protection Agency (2011) produced a comprehensive 
regulatory data dossier on coumatetralyl from which much of the following toxico-
kinetic information was summarized. As with other anticoagulants, in rats coumat-
etralyl is absorbed quickly after oral dosing. Maximum blood concentrations in rats 
occurred at 3 h after single dosing in males and between 8 and 24 h in females, with 
absorbed fraction estimates of 75% and 86% of total dose for males and females, 
respectively. After single oral dosage of radiolabeled coumatetralyl, 49–56% of 
administered radioactivity was retained in the body (excluding the gastrointestinal 
tract). The largest fractions were found in liver (21–25%) and skin (7–16%). All 
other organs retained less than 1% of the dose at sacrifice (Danish Environmental 
Protection Agency 2011). Reported persistence and half-lives of coumatetralyl in 
blood and liver are summarized in Table 4.3. Coumatetralyl has an intermediate 
hepatic persistence in comparison to the SGARs.
The primary route of coumatetralyl excretion in rats is via urine and to a smaller 
extent via feces, with respiratory (exhaled) excretion negligible. The rate of excre-
tion was sex-dependent, where single-dosed males excreted about 20% of an admin-
istered dose in urine and about 20% in feces until sacrifice at 7 days. In comparison, 
single-dosed females excreted about 37% in urine and about 12% in feces. With 
repeated oral dosing, the ratio shifted towards 44% renal and 33% fecal excretion 
until sacrifice, which was possibly due to enzyme induction over a 14 day period 
(Danish Environmental Protection Agency 2011).
Table 4.3 Half-life values reported for coumatetralyl in blood and liver of rodents
Species
Plasma t ½ 
(hours)
Liver t ½ 
(days) Reference
Norway rat 55 Parmar et al. (1987)
Norway rat 62 Eason et al. (2003)
Norway rat 71 (male)
46 (female)
Danish Environmental Protection 
Agency (2011)
House mouse (Mus 
musculus)
12.5 15.8 Vandenbroucke et al. (2008)
Red deer (Cervus 
elaphus scoticus)
18.9 Crowell et al. (2013)
K.E. Horak et al.
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Coumatetralyl is metabolized by hydroxylation, with four metabolites identified 
in urine and feces. In rats, sex and dose did not have major effects on the metabolite 
profiles. One main metabolite comprised 27% of the administered oral dose, with 
three isomers of this main metabolite making up less than 10% of the dose. Two 
further minor metabolites identified in urine (2% of the dose), with only traces of 
unchanged coumatetralyl excreted in urine (Danish Environmental Protection 
Agency 2011).
4.3  Chlorophacinone
As for other first- or intermediate-generation anticoagulants, chlorophacinone is 
most efficacious when consumed in numerous doses over multiple days, i.e., a lethal 
single dose requires a far greater quantity than the additive quantities that constitue 
a lethal multiple/chronic dose (e.g., Jackson and Ashton 1992). In the rat, the main 
route of chlorophacinone elimination is fecal (>99%). Belleville (1977) reported 
that in a study of rats dosed with C14-labelled chlorophacinone, 90% was recovered 
in the feces within 48 h of oral administration and 100% within 4 days. Biliary 
excretion was investigated in this study, and it was found that 8 h after intraduodenal 
chlorophacinone administration, 26% of the radioactivity was found in the bile, 
providing further support that excretion in the feces is the main route of elimination. 
Four hours after a single oral dose, concentration of chlorophacinone in the blood 
reached its peak, and tissue to blood ratios were 4.2 for liver:blood, 0.9 for 
kidney:blood and 0.6 for lung:blood (Belleville 1977). Berny et al. (2006) found the 
oral bioavailability of chlorophacinone to be 92% in sheep with little degradation in 
the rumen. Vein et  al. (2013) found that rats from wild populations with known 
resistance to ARs did not show any differences in profiles of hepatic accumulation 
of chlorophacinone over 4 days following bait ingestion. In the same study, these 
authors described extensive metabolism of chlorophacinone, with similar proportions 
of three hydroxylated metabolite compounds produced by each strain of rat, with 
one dominant metabolite accounting for approximately 50% of residual concentra-
tion in liver.
Two studies have examined chlorophacinone half-life in tissue (Table 4.4). Sheep 
dosed intraruminally with 1  mg chlorophacinone/kg body weight had a time to 
maximum plasma concentration of 30  h in contrast to intravenous dosing with 
peaked values at the time of dosing (Berny et al. 2006). Half-lives of chlorophaci-
none in blood and liver are shown in Table 4.4.
Table 4.4 Half-life values for chlorophacinone in blood and liver
Species Plasma t½ (hours) Liver t½ (days) Reference
Sheep 30.1 Berny et al. (2006)
Mouse 11.7 days 35.4 Vandenbroucke et al. (2008)
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4.4  Diphacinone
Like chlorophacinone, diphacinone is more toxic when ingested as consecutive, 
multiple doses over a number of days (i.e., a lethal single dose requires a far greater 
quantity than the additive quantities that constitue a lethal multiple/chronic dose). 
For rodents, there are highly variable chronic oral toxicity estimates with apparent 
differences in the susceptibility of male and female animals (e.g. Kusano 1974). 
Reported persistence and half-lives of diphacinone in blood and liver are sum-
marised in Table 4.5.
Yu et al. (1982) reported that diphacinone was not extensively metabolised by 
rats following oral administration of C14-labelled diphacinone at 0.2  mg/kg or 
1.5 mg/kg, with more than 60% of the dose excreted in feces and 10% in urine over 
8 days, with the same elimination pattern observed in mice. Continued elimination 
in feces over 4–8 days indicated that biliary excretion rather than incomplete absorp-
tion was the major route of elimination in both rodent species. At 8 days after dos-
ing, rat tissues retained about 20% of radiocarbon (tracer in administered dose), 
with highest concentration in the liver, substantial residues in kidney and lung, and 
lower residues in brain, fat, blood and muscle (Yu et al. 1982). Another study, of 
radio-labelled diphacinone administered orally to mice (Cahill and Crowder 1979) 
reported similar results, with radioactivity reaching highest levels in liver and lungs, 
with maximum liver concentrations at 3.0–7.5 h after administration. In an addi-
tional study of the excretion of radio-labelled diphacinone in mice, Cahill (1977) 
did not detect unchanged diphacinone in feces, indicating the compound was likely 
to be efficiently absorbed in the gastrointestinal tract and extensively metabolised, 
prior to excretion of as-yet undefined metabolites in urine.
In contrast to findings in rodents, Bullard et al. (1976) reported that cows dosed 
with 1  mg/kg diphacinone by intraruminal injection had almost constant liver 
 residues of up to 0.15 mg/g over 30–90 days after dosing. Another study by the 
same group found mammillary transfer of diphacinone to milk of cows dosed 
intraruminally with 2.75 mg/kg. The milk from these cows contained a maximum 
concentration of 0.021 ppm diphacinone. They did not detect any diphacinone in the 
Table 4.5 Half-life values reported for diphacinone in liver. Liver retention is expressed as the 
time period for which residues are reported to persist in the liver unless the value is preceded by t½
Species Liver t½ (days) Reference
Norway rat t½ 3 Fisher et al. (2003)
Cattle (Bos taurus) >90 Bullard et al. (1976)
Deer (Cervus elaphus scoticus) t½ 6 (mean) Crowell et al. (2013)
Pig (Sus scrofa) t½ 5.43–14.12
t½ 12.4
Fisher (2006)
Crowell et al. (2013)
American kestrel (Falco sparverius)
Eastern screech-owl (Megascops asio)
t½ 0.325 (initial)
t½ 2.49 (terminal)
t½ 0.88 (initial)
t½ 29.2 (terminal)
Rattner et al. (2011, 2014)
K.E. Horak et al.
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milk of cows dosed with 1 mg/kg diphacinone, leading to the hypothesis that trans-
fer of diphacinone to the milk is dependent on plasma concentration (Bullard et al. 
1977). Recent research (Crowell et al. 2013) confirms that diphacinone is metabo-
lised and distributed quite differently in cattle compared with in other mammals, 
including exhibiting longer hepatic persistence.
In two studies investigating the effects of anticoagulants to non-target raptors, 
Rattner and colleagues exposed both American kestrels (Falco sparverius) and 
eastern screech owls (Megascops asio) to diphacinone. Kestrels were dosed with 
diphacinone in a gelatin capsule at a range of 35.1–675 mg/kg body weight. In this 
study, birds that succumbed within 24 h had greater liver residue levels than those 
that died 27–47 h post dose, (32.8–56.3 μg/g liver and 13.4–19.4 μg/g liver, respec-
tively). From these data, the clearance of diphacinone from the liver was deter-
mined to be biphasic with an initial half-life of 0.88 days (7.8 h) and a terminal 
half-life of 29.2 days (Rattner et al. 2011). In a separate study, eastern screech owls 
were provided diphacinone mixed into their diet for three or seven days for a 
cumulative average dose of 4.74 mg/kg or 7.98 mg/kg body weight. During the 
dosing period, kidney residue levels were greater than those found in the liver with 
the concentration of diphacinone in both tissues decreasing rapidly in the post-
dose period being <0.1 μg/ g liver after three weeks. Clearance of diphacinone was 
again found to be biphasic and cleared more rapidly from the kidney than the liver. 
Initial half-life was found to be 0.88 days in liver and 0.14 days in kidney while 
terminal half-life (day 4–21 post-dose) in liver of 29.2 days and kidney 10.2 days 
(Rattner et al. 2014).
4.5  Pindone
Reported persistence and half-lives of pindone in blood and liver are summarised in 
Table 4.6. In mammals, pindone is far less persistent than SGARs and also less 
persistent in liver than other FGARs. In dogs, pindone was fairly well absorbed 
(67%) but tissue distribution appeared to be slightly different from other anticoagu-
lants, as plasma concentrations remained higher than tissue concentrations for 
8 days, while concentrations in liver and kidney were comparable (Fitzek 1978). 
Table 4.6 Half-life estimates for pindone in blood and liver
Species Plasma t½ (hours) Liver t½ (days) Reference
Norway rat 2.1 Fisher et al. (2003)
Dog 120 Fitzek (1978)
Dog 45.6 Martin et al. (1991)
Sheep 8–16 Nelson and Hickling (1994)
Sheep 96–120 Robinson et al. (2005)
Cattle 74.4 Martin et al. (1991)
Chicken 67.2 Martin et al. (1991)
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In sheep, residues were detected in the liver and fat of dosed animals for 8 days, 
but after 2  weeks no residues were detectable (Nelson and Hickling 1994). No 
information was found about the excretion profile of pindone.
4.6  Brodifacoum
After ingestion and absorption of brodifacoum by mammals, high concentrations 
are bound in the liver and remain stable, being slowly metabolised and excreted 
(Erickson and Urban 2004). The persistence of brodifacoum in mammalian liver is 
well documented and is in contrast with its more rapid elimination from blood 
(Table 4.7). While no hepatic half-life values were found for avian species, limited 
data suggests that birds have similarly prolonged persistence of brodifacoum in 
liver. Brodifacoum concentrations in chicken livers showed little variation (mean 
0.66, range 0.45–1.00 μg/g) over 14 days following sublethal oral exposure (Fisher 
2009). Similarly, in Japanese quail (Coturnix japonica) orally administered brodifa-
coum (0.8 and 2.5 mg/kg body weight), there was no substantial decline in hepatic 
concentrations over the following 5 days (Webster et al. 2015).
Table 4.7 Half-life values reported for brodifacoum in blood plasma/serum and liver following a 
range of exposure levels and routes of administration. Liver retention is expressed as the time 
period for which residues are reported to persist in the liver unless the value is preceded by t½. 
Plasma is t½ unless otherwise specified
Species Plasma t½ (hours)
Liver retention 
(days) Reference
Rat t½ 350 Batten and Bratt (1990)a
Rat t½ 128 (terminal) Batten & Bratt (1990)a
Rat t½ 282 Hawkins et al. (1991)a
Rat t½ 150–200 Bratt & Hudson (1979)a
Rat t½ 136 Belleville (1991)a
Rat 156 (serum) >80 Bachmann and Sullivan (1983)
Rat t½ 130 Parmar et al. (1987)
Rat t½ 113.5 Fisher et al. (2003)
Mouse 2200.8 t½ 307.4 Vandenbroucke et al. (2008)
Rabbit 60.8 ± 1.9 (terminal) Breckenridge et al. (1985)
Dog 144 Woody et al. (1992)
Dog 21.6–112.8 Robben et al. (1998)
Dog 1.4 (initial)
8.7 (terminal)
Murphy et al. (1985)
Possum 480–720 >252 Eason et al. (1996)
Sheep >250 Laas et al. (1985)
Horse 28.8 Boermans et al. (1991)
Chicken 27.36 Fisher (2009)
aUnpublished reports cited by Erickson and Urban (2004)
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Bachmann and Sullivan (1983) suggested that serum and liver concentrations of 
brodifacoum were likely to accumulate with repeated daily exposures, based on simu-
lations of the data they obtained following a single 0.2 mg/kg dose to laboratory rats. 
The major route of excretion of unbound brodifacoum in mammals is through feces 
(Sutcliffe et al. 1987). Field observations of rodent feces colored to different extents 
by the green or blue dyes used in anticoagulant bait formulations are common - an 
estimated 14–21.6% of ingested brodifacoum is excreted unchanged in rat feces in 
the period between ingestion of a lethal amount of bait and death (Fisher 2009).
To better understand the pharmacokinetic properties of brodifacoum, Bachmann 
and Sullivan (1983) gavaged male Sprague Dawley rats with varying doses of brodi-
facoum in polyethylene glycol 400. They found that metabolic processes play a 
significant role in the efficacy of brodifacoum as pretreatment with SKF525A, a 
non-selective cytochrome P450 inhibitor, increased the anticoagulant effect whereas 
phenobarbital, cytochrome P450 inducer, decreased the anticoagulant effects 
(Bachmann and Sullivan 1983).
4.7  Bromadiolone
Absorption of bromadiolone in laboratory rats was >70% of the administered dose, 
based on carcass, bile and urinary excretion measurements (European Food Safety 
Authority 2010). In rats given an oral dose of radiolabelled bromadiolone, within 
48 h approximately 53% of was excreted in feces and <1% in urine (European Food 
Safety Authority 2010). It seems that biliary elimination plays a major role, with 
about 30% of an administered bromadiolone dose excreted in bile in the 8 h after 
dosing (Nahas 1987). Bromadiolone is extensively metabolised to at least 10 minor 
metabolites and 1 major metabolite, tentatively identified as a benzylic carbon 
hydroxylated analogue of the parent compound. This metabolite is conjugated with 
glucuronic acid before excretion in bile and hydrolysis in the gastrointestinal tract 
(European Food Safety Authority 2010).
After oral administration to rats, bromadiolone was eliminated relatively quickly 
from blood, resulting in high concentrations in liver tissues (Kamil 1987). 
Elimination of radiolabelled bromadiolone from rat liver is reported to be biphasic, 
consisting of a rapid initial phase lasting from 2 to 8 days after dosing and a slower 
terminal phase (Anonymous 2010). Reported persistence and half-lives of broma-
diolone in blood and liver are summarised in Table 4.8, noting an unusually long 
half-life in blood of mice (Vandenbroucke et al. 2008). In a study using pigs, Enouri 
et al. (2015) dosed two treatment groups with either 0.05 or 0.5 mg/kg bromadio-
lone and euthanized sub-groups at time points up to 9 weeks. Detectable levels of 
bromadiolone were found in liver, skin and adherent fat, feces, and plasma three 
week post-dosing. As expected, liver tissue had the highest bromadiolone residue 
concentrations. Liver values for pigs dosed with 0.05 mg/kg were 51.8 μg/g at six 
weeks while pigs dosed with 0.5  mg/kg bromadiolone had liver residues of 
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213.9 μg/g at nine weeks post dosing. The authors also reported a biphasic depletion 
of bromadiolone in the feces and that clearance was not dose-dependent in liver and 
muscle tissues as the slope of the concentration vs time graphs were the same 
regardless of dose administered (Enouri et al. 2015).
4.8  Difenacoum and Difethialone
There is limited information about the pharmacokinetics of difenacoum or difethi-
alone. Vandenbroucke et al. (2008) cite an unpublished report (Bratt 1987) where an 
oral dose of radiolabelled difenacoum (1.2 mg⁄ kg) administered to rats produced 
the highest concentration of radioactivity in liver after 24 h, indicating a similar 
timeframe of absorption as other anticoagulant compounds. Biphasic elimination of 
difenacoum from liver and a terminal half-life of elimination of 118 days is also 
cited (Vandenbroucke et al. 2008). In a 1985 study by Breckenridge and coworkers, 
male New Zealand rabbits were intravenously dosed with difenacoum dissolved in 
polyethylene glycol 200. Difenacoum exhibited a biphasic decay in the plasma with 
a terminal half-life of 83.1 h. This terminal half-life is much great than that for war-
farin, which was attributed to difenacoum’s greater volume of distribution relative 
to warfarin (Breckenridge et al. 1985). In their assessment of multiple anticoagulant 
compounds in mice, Vandenbroucke et  al. (2008) estimated plasma elimination 
half-lives of 20.4 and 38.9 days for difenacoum and difethialone, respectively, and 
liver elimination half-lives of 61.8 and 28.5 days, respectively. In a study of dogs 
administered a range of anticoagulant compounds, Robben et al. (1998) estimated 
plasma half-life of difethialone in two animals of 2.2 and 3.2 days. More recently, 
Damin-Pernik et  al. (2016a) showed that while cis- and trans-isomers of difena-
coum were similarly absorbed after oral administration to laboratory rats, in liver 
the half-life of the trans-isomers were 24.2  h compared to 706  h for the 
cis-isomers.
Table 4.8 Half-life values reported for bromadiolone in blood and liver following a range of 
exposure levels and routes of administration. Liver retention is expressed as the time period for 
which residues are reported to persist in the liver unless the value is preceded by t½
Species
Blood t½ 
(hours)
Liver retention 
(days) Reference
Norway rat (Rattus 
norvegicus)
26–57 Kamil (1987)
Norway rat 25–26 t½ 170 Parmar et al. (1987)
Rat 318 European Food Safety Authority 
(2010)
Sheep 256 Nelson and Hickling (1994)
Mouse 33.3 days 28.1 Vandenbroucke et al. (2008)
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4.9  Flocoumafen
In rats, absorption of orally-administered flocoumafen is rapid, reaching a maxi-
mum concentration in blood after 4 h and falling to half-maximum by 8 h (Huckle 
et al. 1989a). The persistence of flocoumafen in liver is of a similar extent to that of 
brodifacoum (Table 4.9). A plasma half-life of flocoumafen in mice was estimated 
as 26.6 d (Vandenbroucke et al. 2008), consistent with the overall shorter retention 
time of anticoagulants in blood compared to liver.
Following administration of flocoumafen, liver residues in rats consisted mainly 
of unchanged flocoumafen, although in a repeat-dose study a polar metabolite was 
also detected. Eight urinary metabolites were detected after percutaneous exposure 
to 14C–flocoumafen but represented a small proportion of the total dose, with most 
excretion occurring in the feces as unchanged flocoumafen (Huckle and Warburton 
1986 cited by Eason and Wickstrom (2001)). Veenstra et al. (1991) found retention 
of about 8% of an administered flocoumafen dose of 0.4 mg/kg in the liver of beagle 
dogs 300 days after dosing. When oral 14C–flocoumafen doses of 0.02 mg/kg or 
0.1 mg/kg body weight were given to rats, once weekly for up to 14 weeks, approxi-
mately one-third of each weekly low dose was eliminated through the feces within 
3 days, mostly within the first 24 h. At the higher dose, the fecal excretion ranged 
from 18% after the first dose to 59% after the 10th dose (Huckle et al. 1988). This 
study indicated the potential of flocoumafen to bioaccumulate in rat liver, as hepatic 
residues increased throughout the 14 week repeat-dosing period.
Japanese quail metabolize flocoumafen more rapidly than rats, with a proportion 
of an administered dose retained in the liver and an elimination half-life of 155 days. 
In quail, fecal excretion of radio-labelled flocoumafen following an oral dose of 
0.14 mg/kg body weight accounted for 23–26% of the dose over the 7-day period; 
approximately half of this was recovered within the first 24 h with less than 0.5% of 
the dose excreted in urine within 7 days (Huckle et al. 1989b).
In a dietary toxicity study, 30-week-old laying hens were fed a diet designed to 
produce different exposures to flocoumafen (1.5, 5, 10 and 50  mg/kg) over five 
consecutive days (Eadsforth et al. 1993). The LC50 at the end of a 28-day observa-
tion period was 16.4 mg/kg. Livers of birds administered 5–50 mg/kg had concen-
trations of flocoumafen (1.5 nmol/g) that were independent of dose, indicating a 
Table 4.9 Half-life values reported for flocoumafen in liver following a range of exposure levels 
and routes of administration. Liver retention is expressed as the period for which residues are 
reported to persist in the liver unless the value is preceded by t½
Species Liver retention (days) Reference
Norway rat (Rattus norvegicus) t1/2 220 Huckle et al. (1988)
Sheep >256 Nelson and Hickling (1994)
Quail (Coturnix coturnix) t1/2 > 100 Huckle et al. (1989b)
Dog >300 Veenstra et al. (1991)
Mouse (Mus musculus) 93.8 Vandenbroucke et al. (2008)
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saturable high-affinity binding site in liver. While residual flocoumafen in the 
corresponding muscle samples was at relatively low concentrations in all treatment 
groups, higher dose-related residues were found in samples of abdominal and 
skin- associated fat and there was clear evidence of the transfer of dose-related resi-
dues into eggs. Eadsforth and colleagues also describe another study in which hens 
were dosed with [14C]flocoumafen for five consecutive days at a daily rate of 1 mg/
kg or 4 mg/kg body weight, where 68% of the daily radioactive dose was eliminated 
over the following 24 h via excreta (Eadsforth et al. 1993). Residues in liver at death 
through poisoning or at euthanasia accounted for <1% of the cumulative adminis-
tered radioactivity. Residues in eggs at 10 days after first exposure were primarily in 
the yolk with maximum concentrations of 1.0 mg/kg (0.18% of the low dose) and 
2.1 mg/kg (0.06% of the high dose), with 40% of the total activity in the yolk 
comprising unchanged flocoumafen (measured as 14C- flocoumafen equivalents).
5  Toxicokinetics of Anticoagulant Rodenticides
While the mechanism of action of warfarin (i.e., coumadin) and its time course of 
therapeutic effect (i.e., prolonged prothrombin time) have been thoroughly investi-
gated in man (e.g., Holford 1986; Sutcliffe et al. 1987), remarkably few studies have 
examined the time course of AR toxicity (i.e., coagulopathy) and clotting time 
recovery that accompanies exposure in non-target animals. Following administra-
tion of a therapeutic dose or a toxic dose(s) and the inhibition of vitamin K epoxide 
reductase, there is a lag period of several days prior to the appearance of prolonged 
clotting time. This lag period (2–3 days) reflects the clearance half-life of fully- 
functional coagulation factors, for example, half-life of factors II, VII, IX and X in 
man are 120 h, 6 h, 18 h and 65 h, respectively(Lee et al. 2006) accompanied by the 
appearance of increasing quantities of des-carboxy dysfunctional factors that are 
unable to assemble on cell surfaces to form active coagulation complexes. A detailed 
study in which domestic cats received a single intravenous bolus dose of racemic 
warfarin (0.5  mg/kg) describes maximum prothrombinopenic effects within 
24–48 h, and recovery of prothrombin complex activity to pre-exposure baseline 
levels within 70 h (Smith et al. 2000b). However, in this study inter-individual varia-
tion among cats was substantial, as has been noted in man. A study in domestic dogs 
administered warfarin (5 mg/kg) or diphacinone (2.5 mg/kg) as divided doses for 
3 days demonstrated prolonged clotting time within 2–3 days (Mount and Feldman 
1983). While administration of a single dose of vitamin K1 (5  mg/kg) restored 
clotting function in the warfarin-treated dog within 24–48 h, multiple vitamin K1 
doses were required in diphacinone-dosed dogs as they exhibited impaired clotting 
function for as long as 30 days.
Few studies have examined toxicokinetics of ARs in non-target wildlife. Dietary 
exposure of golden eagles (Aquila chrysaetos) to 2.7 μg diphacinone/g ww resulted 
in prolonged clotting time within 5 days with coagulopathy apparent at least 5 days 
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post-exposure (Savarie et  al. 1979). Similarly, Eastern screech-owls (Megascops 
asio) fed a diet containing 10 μg diphacinone/g ww exhibited coagulopathy within 
3  days, and upon termination of exposure clotting function was restored within 
4 days (Rattner et al. 2014). As alluded to in Chap. 3 of the text, latent episodes 
of hemorrhage, occurring days to weeks following termination of AR exposure, 
have been observed in some trials in non-target wildlife.
6  Conclusions
Although ARs have been in use for decades, there are relatively little data on the 
ADME properties and binding properties of these compounds. These data are 
challenging to obtain but are invaluable for many reasons. ADME data is important 
for the basic understanding of anticoagulant compounds enabling scientists to 
compare anticoagulants to other classes of contaminants and therapeutics. These data 
are also used to evaluate the comparative efficacy of anticoagulants and to develop 
hazard and risk assessments. These risk assessments are used by the US EPA and 
comparative international agencies to evaluate registration and use of these products. 
ADME data is often used in risk assessment models; therefore, the better the pool 
of data from which to draw, the more robust the risk assessment.
Numerous areas of research of anticoagulants may need further study to deter-
mine what, if any, effect role they play in non-target risk. These include placental 
and in ovo transfer of residues. Both of these may represent significant routes 
of exposure to anticoagulant compounds, and surprisingly have not been well- 
characterized. Also, fecal excretion of anticoagulants has not been well studied. 
Fecal excretion may contribute significantly to the transfer of anticoagulant com-
pounds across the environment. From the few available reports, excretion of parent 
compound or metabolite is compound dependent with some anticoagulants being 
excreted in the feces as metabolites while others are excreted in high percentages 
as parent compound.
Additional studies investigating basic ADME properties of anticoagulants need 
to be conducted. These include competitive binding studies to determine the active 
binding sites of these compounds. This information would both improve risk assess-
ments when exposure to multiple compounds is being considered and to assess the 
potential for cumulative toxicities. Recently published studies have examined the 
pharmacokinetic properties of various SGAR diastereoisomers and their ability to 
inhibit vitamin K epoxide reductase (VKOR) (Damin-Pernik et al. 2016a, b). It was 
demonstrated that cis- and trans- SGAR isomers exhibit similar potency in their 
ability to inhibit VKOR, but their pharmacokinetic properties differ considerably. 
This research team has suggested that it might be possible to create eco-friendly 
baits that are efficacious in controlling pest species, but with the shorter tissue 
half- life SGAR isomer that would pose less risk to non-target predators consuming 
poisoned prey.
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